drugset / Trial / NCT03841474
The Recovery of Cardiovascular Patients With Depression
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Cardiovascular disease increases the risk of depression and vice versa. Many cardiovascular patients are subjected to percutaneous coronary intervention (PCI). Potential biomarkers for the development, the course and the recovery of both diseases are in the focus of interest of many studies. One of the biomarkers that stands out is brain derived neurotrophic factor (BDFN). BDNF plays a significant role in regulating vascular growth and repair but also stimulates the survival, differentiation, and conservation of neurons. The aim of the study is to detect the depression in patients undergoing PCI and to determine the impact of psychiatric treatment on the functional recovery and on the changes of BDNF.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2021-06-01
- Completion
- 2021-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Escitalopram | Small molecule | 10 mg | — |
| Subject | Escitalopram | Small molecule | 20 mg | — |
| Subject | Sertraline | Small molecule | 50 mg | — |
| Subject | Sertraline | Small molecule | 200 mg | — |